1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2302, 2009-015459-25, NCT01223027
|
|
2.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2008-0510, NCT00831792
|
|
3.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2208, NCT01232296
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0296, NCT01262027
|
|
5.
|
Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0650, NCT01266070
|
|
6.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2211, 2011-000266-35, NCT01379534
|
|
7.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: H-1012-047-344, NCT01417143
|
|
8.
|
Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: AMC1101, NCT01440959
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258AIC02, 2011-001725-24, NCT01478373
|
|
10.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IRB-HSR# 15627, NCT01524692
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2210, 2011-001230-42, NCT01528345
|
|
12.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A1201, NCT01576380
|
|
13.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: UCDCC#231, CTKI258AUS21T, NCT01676714
|
|
14.
|
Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: OCOG-2012-DOVE, NCT01678105
|
|
15.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2124, 2011-000103-41, NCT01443481
|
|
16.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11-0946, NCT01496534
|
|
17.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: I 175610, NCI-2010-02034, NCT01497392
|
|
18.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: LUN0044, NCI-2011-03333, SU-08012011-8166, NCT01515969
|
|
19.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 76 Sponsor: Other Protocol IDs: CNIO-BR-01-2011, NCT01548924
|
|
20.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2119, 2011-001489-16, NCT01596647
|
|
21.
|
Phase: Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CTKI258AU012T, NCT01680796
|